医药公司将在11月19日报告2025年Q3结果,并主持11月20日的电话会议,讨论未来业绩和风险。 Medicure Inc. will report Q3 2025 results on Nov. 19 and host a Nov. 20 call discussing future performance and risks.

Medicure Inc. 将于 2025 年 11 月 19 日收盘后发布 2025 年第三季度财务业绩，并于美国东部时间 11 月 20 日上午 8：30 举行电话会议讨论业绩。 Medicure Inc. will release its Q3 2025 financial results after the market close on November 19, 2025, and hold a conference call on November 20 at 8:30 AM ET to discuss performance. 该电话可通过电话和网播收听,其中将包括关于未来收入、产品业绩和监管成果的前瞻性说明,并指出,由于外部风险,实际结果可能有所不同。 The call, accessible by phone and webcast, will include forward-looking statements about future revenues, product performance, and regulatory outcomes, with a note that actual results may vary due to external risks. 该公司通过其附属药剂公司在美国销售AGGRASTAT和ZYPITAMAGAG, 经营药店子公司,提供诸如家产和全国综合服务等服务。 The company, which markets AGGRASTAT® and ZYPITAMAG® in the U.S. through its subsidiary Medicure Pharma Inc., operates pharmacy subsidiaries providing services like home delivery and compounding nationwide.